FDA Brief: Week of Feb 8, 2016


FDA approved





Sernivo (betamethasone dipropionate) Spray, 0.05%

Promuis Pharma,  Princeton, New Jersey, USA

Indication: treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.

Reg Pathway: 505 (b)(2)

Mechanism of Action: Steroid. Precise mechanism of action of spray in psoriasis is unknown.


  • 2 multi-center, randomized, double-blind; moderate plaque psoriasis; 28 days; Sernivo vs. Vehicle
  • Primary Endpoint: Investigator Global Assessment (IGA) score of  0 or 1 [clear or almost clear] and at least a 2-scale reduction from baseline
  • Treatment success of 42.7% and 34.5% vs. 11.7% and 13.6%, respectively (p<0.001).


  • Warnings/Precautions: Reversible HPA axis suppression, Cushing’s syndrome, hyperglycemia and unmasking of latent diabetes mellitus
  • Most common adverse reactions : Application site reactions, including pruritus, burning and/or stinging, pain, and atrophy




Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo

You are commenting using your Google account.
Log Out / 
Change )

Twitter picture

You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo

You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s